Intro offer
100 days of Premium for just $10.
Try all Premium features for over 3 months and analyze stocks without limits.
Try 100 days for $10

$13.11
0.85%
Nasdaq, Sep 16, 10:00 am EDT. Market open.
ISIN
US09075A1088
Symbol
BVS

Bioventus Inc - Ordinary Shares - Class A Target price 2026 - Analyst rating & recommendation

Bioventus Inc - Ordinary Shares - Class A Classifications & Recommendation

Buy
89%
Hold
11%

Bioventus Inc - Ordinary Shares - Class A Price Target

Target Price $18.36
Price $13.00
Potential
Number of Estimates 6
6 Analysts have issued a price target Bioventus Inc - Ordinary Shares - Class A 2027 . The average Bioventus Inc - Ordinary Shares - Class A target price is $18.36. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 8 Analysts recommend Bioventus Inc - Ordinary Shares - Class A to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bioventus Inc - Ordinary Shares - Class A stock has an average upside potential 2027 of . Most analysts recommend the Bioventus Inc - Ordinary Shares - Class A stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 568.09 610.28
0.91% 7.43%
EBITDA Margin 10.92% 20.30%
115.44% 85.94%
Net Margin 4.00% 10.84%
163.49% 170.92%

6 Analysts have issued a sales forecast Bioventus Inc - Ordinary Shares - Class A 2026 . The average Bioventus Inc - Ordinary Shares - Class A sales estimate is

$610m
unlock
. This is
4.89% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$636m 9.32%
unlock
, the lowest is
$590m 1.40%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $568m 0.91%
2026
$610m 7.43%
unlock
2027
$653m 6.96%
unlock
2028
$693m 6.16%
unlock
2029
$745m 7.44%
unlock
2030
$801m 7.63%
unlock

6 Analysts have issued an Bioventus Inc - Ordinary Shares - Class A EBITDA forecast 2026. The average Bioventus Inc - Ordinary Shares - Class A EBITDA estimate is

$124m
unlock
. This is
89.42% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$130m 98.93%
unlock
, the lowest is
$119m 82.39%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $62.0m 113.49%
2026
$124m 99.74%
unlock
2027
$137m 10.77%
unlock
2028
$151m 9.90%
unlock
2029
$168m 11.41%
unlock
2030
$191m 13.41%
unlock

EBITDA Margin

2025 10.92% 115.44%
2026
20.30% 85.94%
unlock
2027
21.02% 3.55%
unlock
2028
21.76% 3.52%
unlock
2029
22.57% 3.72%
unlock
2030
23.78% 5.36%
unlock

6 Bioventus Inc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2026. The average Bioventus Inc - Ordinary Shares - Class A net profit estimate is

$66.2m
unlock
. This is
21.52% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$69.7m 27.95%
unlock
, the lowest is
$63.4m 16.40%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $22.7m 162.91%
2026
$66.2m 191.16%
unlock
2027
$76.1m 14.94%
unlock
2028
$87.0m 14.32%
unlock
2029
$90.8m 4.39%
unlock
2030
$104m 14.95%
unlock

Net Margin

2025 4.00% 163.49%
2026
10.84% 170.92%
unlock
2027
11.65% 7.47%
unlock
2028
12.55% 7.73%
unlock
2029
12.19% 2.87%
unlock
2030
13.02% 6.81%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ 0.33 0.79
158.93% 139.39%
P/E 16.50
EV/Sales 2.17

6 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast for earnings per share. The average Bioventus Inc - Ordinary Shares - Class A EPS is

$0.79
unlock
. This is
1.28% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$0.83 6.41%
unlock
, the lowest is
$0.75 3.85%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $0.33 158.93%
2026
$0.79 139.39%
unlock
2027
$0.91 15.19%
unlock
2028
$1.04 14.29%
unlock
2029
$1.08 3.85%
unlock
2030
$1.24 14.81%
unlock

P/E ratio

Current 16.67 102.31%
2026
16.50 1.00%
unlock
2027
14.35 13.03%
unlock
2028
12.56 12.47%
unlock
2029
12.03 4.22%
unlock
2030
10.46 13.05%
unlock

Based on analysts' sales estimates for 2026, the Bioventus Inc - Ordinary Shares - Class A stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.27 40.12%
2026
2.17 4.62%
unlock
2027
2.02 6.50%
unlock
2028
1.91 5.81%
unlock
2029
1.77 6.92%
unlock
2030
1.65 7.09%
unlock

P/S ratio

Current 1.88 77.31%
2026
1.79 4.66%
unlock
2027
1.67 6.50%
unlock
2028
1.58 5.80%
unlock
2029
1.47 6.92%
unlock
2030
1.36 7.09%
unlock

Current Bioventus Inc - Ordinary Shares - Class A Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Canaccord Genuity
Locked
Locked
Locked Aug 17 2026
Cantor Fitzgerald
Locked
Locked
Locked Aug 17 2026
Barrington Research
Locked
Locked
Locked Jun 30 2026
Canaccord Genuity
Locked
Locked
Locked Jun 16 2026
Barrington Research
Locked
Locked
Locked May 22 2026
Barrington Research
Locked
Locked
Locked Mar 06 2026
Craig-Hallum
Locked
Locked
Locked Mar 06 2026
Analyst Rating Date
Locked
Canaccord Genuity:
Locked
Locked
Aug 17 2026
Locked
Cantor Fitzgerald:
Locked
Locked
Aug 17 2026
Locked
Barrington Research:
Locked
Locked
Jun 30 2026
Locked
Canaccord Genuity:
Locked
Locked
Jun 16 2026
Locked
Barrington Research:
Locked
Locked
May 22 2026
Locked
Barrington Research:
Locked
Locked
Mar 06 2026
Locked
Craig-Hallum:
Locked
Locked
Mar 06 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today